By Michael Alvear, Health Author & Independent Researcher
My research is published on these scholarly platforms:
Last Updated:
Studies Show IV Ketamine Outperforms Spravato Across Most Measurable Clinical Metrics
▶ Important Context
No direct head-to-head comparisons have been conducted between IV ketamine and Spravato. The comparative findings presented here come from multiple sources: systematic reviews that indirectly compare results from separate placebo-controlled trials of each treatment, independent observational studies examining each treatment’s real-world outcomes, and pharmacological measurements (such as bioavailability data). While this approach provides valuable insights into how the treatments differ, direct head-to-head clinical trials would offer more definitive conclusions about their relative effectiveness.
100% Bioavailability vs 48%
IV ketamine achieves 100% bioavailability compared to Spravato’s 48%, meaning the full medication dose reaches your bloodstream rather than losing more than half through nasal absorption.
⚡
Faster and Higher Remission Rates in The Short Term
- Up to 43% of patients reach remission after just 1–2 IV infusions. It takes Spravato the full 21-treatment course to approach these numbers.
- Multiple systematic reviews confirm IV ketamine’s superior remission rate
- One study showing 152% higher than esketamine’s remission rate
- Another finding it 2.52 times more effective at ending depression
- Important limitation: Most systematic reviews measure response and remission rates after just one or two infusions, typically within a few days—revealing ketamine’s rapid action but telling us little about long-term outcomes
?
IV’s Long-Term Remission Rates Remain Unknown
Long-term data on IV ketamine therapy is limited to non-existent in published literature, with most studies capping at six infusions. Individual studies report varying results—from 79% remission at 9 months to 46% at 12 months—but these lack the controlled rigor needed for definitive conclusions.
Why the research gap exists: Ketamine is an inexpensive generic drug with no patent protection. Long-term clinical trials cost millions of dollars, and without a commercial profit motive, pharmaceutical companies won’t fund them. This leaves a critical knowledge gap about what matters most to patients—the likelihood that a full treatment protocol can end or substantially reduce their depression over time.
Fewer Sessions Required With IV
Treatment requires 11–18 sessions over 6 months versus Spravato’s 21 sessions—up to 10 fewer appointments disrupting your life.
⏱️
IV Requires Shorter Time Per Visit
Each IV visit averages 1 hour 43 minutes compared to Spravato’s 2 hours 15 minutes, saving 32 minutes per session.
⚖️
IV Offers Precise Weight-Based Dosing
IV ketamine uses precise weight-based dosing (0.5 mg/kg) tailored to your body, ensuring optimal therapeutic effects while minimizing side effects. This personalized approach means a 120-pound patient receives exactly 27mg while a 200-pound patient receives 45mg—each dose calibrated for maximum effectiveness.
The problem with fixed dosing: Spravato offers only two fixed doses (56mg or 84mg) regardless of body size. This means smaller patients may experience unnecessarily intense side effects from receiving too much medication, while larger patients may receive subtherapeutic doses that reduce the treatment’s effectiveness—both undermining the goal of safe, effective depression relief.
IV Has Broader Molecular Composition
IV ketamine contains both R-ketamine and S-ketamine molecules for broader therapeutic effects, whereas Spravato contains only S-ketamine, potentially limiting long-term effectiveness.
✓
IV Has a Lower Dropout Rate
These advantages translate to a 24% lower dropout rate for IV ketamine, demonstrating that patients find it more effective and sustainable.
Ready for a deeper dive? We’ve organized everything you need to know into 10 comprehensive sections.
↓
Click any card to jump directly to that section
Can’t Decide Between IV, Injections, Or Spravato?
Use My Decision Table
This report ranks all three options—IV, injection, and Spravato—on effectiveness, cost, fastest relief, and more, giving you a clear framework to decide.
Downloads as PDF • 5 minute read
Which Treatment Works Best for Depression—IV Infusions (Ketamine) or the Nasal Spray Spravato (Esketamine)?
IV Ketamine vs Spravato: What Clinical Studies Show
The available evidence indicates that IV ketamine produces larger and faster reductions in depression symptoms during the initial treatment phase compared to Spravato. However, an important methodological limitation prevents us from drawing conclusions about longer-term comparative effectiveness.
Why Direct Comparisons Between IV Ketamine and Spravato Are Difficult
When researchers review the literature, they encounter a significant mismatch: most IV ketamine studies measure outcomes after only one or two infusions—typically within a few days—while Spravato trials commonly follow patients through 8–24 treatment sessions over weeks or months. This creates what researchers call a comparison bias. We’re essentially looking at early snapshots of one treatment versus extended follow-up of another.
Additionally, many IV ketamine studies don’t consistently report the number of infusions participants received, making it difficult to establish dose-response relationships or durability patterns.
Why Long-Term IV Ketamine Studies Are Missing
The disparity in study design reflects economic realities rather than scientific choice. Spravato, manufactured by Johnson & Johnson, is a branded pharmaceutical product that generates revenue to fund extensive clinical trials with long follow-up periods. IV ketamine is an inexpensive generic medication with no patent protection, which means no company stands to profit from funding large-scale, long-term studies. This funding gap doesn’t diminish the validity of existing IV ketamine research—it simply limits the timeframe we can evaluate.
How IV Ketamine and Spravato Compare in Clinical Studies
When researchers pool data from multiple studies, several patterns emerge:
-
●
Effect sizes: IV ketamine demonstrates larger standardized mean differences compared to esketamine, indicating greater reductions in depression symptom scores during the acute treatment phase.
-
●
Response rates: Patients receiving IV ketamine show approximately three times greater likelihood of clinical response (typically defined as ≥50% symptom reduction) compared to placebo. Esketamine’s advantage over placebo is more modest.
-
●
Early remission rates: Studies report that up to 43% of patients achieve remission—meaning their symptoms fall to minimal or subclinical levels—after just one or two IV ketamine infusions. These are acute-phase outcomes that don’t necessarily predict maintenance of benefit.
What the Evidence Does (and Doesn’t) Tell Us About Long-Term Effectiveness
Supported by current evidence: During the initial treatment phase, IV ketamine produces larger, faster symptom reductions than esketamine nasal spray. A subset of patients achieve remission within the first few treatments.
Not supported by current evidence: Whether this early advantage translates to superior long-term outcomes remains unknown. The different study durations and inconsistent reporting of infusion counts make medium- to long-term comparisons unreliable.
Summary: Which Treatment Is More Effective?
The research consistently demonstrates IV ketamine’s superior effectiveness during the acute treatment phase. Whether this advantage persists over extended treatment courses cannot be determined from existing studies due to fundamental differences in how the treatments have been evaluated. Until research protocols measure both treatments over comparable timeframes with similar follow-up periods, conclusions about long-term comparative effectiveness remain speculative rather than evidence-based.
How Fast Does IV Ketamine Work Compared to Spravato for Depression?
IV ketamine achieves remission faster in the short term and requires up to 10 fewer sessions to complete treatment—meaning patients can move through the acute phase more quickly and return to normal functioning sooner.
How Quickly Does IV Ketamine Achieve Remission?
IV ketamine produces rapid results: up to 43% of patients reach remission after just one or two infusions—an unusually high early-remission rate for treatment-resistant depression, and a sign of a strong acute antidepressant effect.
But we simply don’t know the true long-term remission rates for IV ketamine, because the large, multi-year studies needed to measure durability haven’t been funded; ketamine is a cheap, off-patent generic, so no pharmaceutical company can make enough profit to justify spending millions on those trials.
Spravato typically requires several weeks of treatment before significant relief occurs. When you’re struggling with severe depression, that time difference can feel critical.
How Many Treatment Sessions Required: IV Ketamine vs Spravato
Beyond initial relief, the total number of sessions required affects how quickly you can complete your acute treatment phase:
Why Fewer Treatment Sessions Mean Faster Recovery From Depression
Completing treatment in 11–18 sessions versus 21 sessions means you move through the acute phase faster and reach the maintenance stage sooner. This translates to a quicker return to work, relationships, and daily functioning—you’re not spending months cycling through intensive treatment sessions when you could be rebuilding your life.
This speed advantage appears to matter: one major review found dropout rates were 24% lower for IV ketamine than Spravato, suggesting that faster, more substantial early relief helps patients stay engaged with treatment.
Summary: Speed of Relief With IV Ketamine vs Spravato
IV ketamine achieves remission faster in the short term (within 1–2 infusions for many patients) and requires significantly fewer total sessions to complete acute treatment—though long-term comparative data remains limited. For patients in crisis, both the rapid initial relief and the shorter path through intensive treatment can be meaningful factors in recovery.
How “Bioavailability” May Explain The Difference in Effectiveness Between IV Ketamine and Spravato
This section explains how IV ketamine and Spravato differ in drug delivery, absorption rate, and how long the medication stays active in your body—covering why IV tends to work faster and last longer.
If the treatment can’t reach your brain, it can’t do its job. That’s what makes IV ketamine so different from the Spravato nasal spray. IV ketamine gets 100% of the drug directly into your bloodstream. Nothing is lost. Nothing is filtered out. That full-strength dose moves fast—and hits hard.
In contrast, Spravato (esketamine) nasal spray has a bioavailability of about 48%. This means that if you’re prescribed an 84mg dose, around 40mg of the medication will actually be absorbed.
Spravato’s High Dose Makes Up for Low Absorption – But There’s a Catch
Let’s be fair – the makers of Spravato aren’t ignoring the fact that less medicine gets absorbed through your nose. They handle this by giving you a higher dose (84mg) knowing that only about half will make it into your bloodstream. On paper, this seems like a perfect solution.
But here’s the real issue: nasal absorption isn’t reliable or consistent. Think about the last time you had a cold or allergies. Your nose wasn’t working quite right, was it? The same problem affects how well Spravato gets absorbed. The expected 48% absorption rate can drop even lower due to:
-
●
A stuffy or runny nose
-
●
Seasonal allergies
-
●
Sinus problems
-
●
Post-nasal drip (when mucus runs down the back of your throat)
-
●
Not using the nasal spray correctly (it’s trickier than it sounds)
This means that even though you’re getting the same dose each time, your body might absorb different amounts from one treatment to the next. One day you might get the full 48% absorption, but the next time it could be much less if you’re congested or not feeling well.
IV ketamine doesn’t have this problem. When it goes directly into your vein, you get 100% of the medicine every single time – no guesswork, no variation, no wondering if your stuffy nose is getting in the way of your treatment.
Why IV Infusions Provide the Full Impact
IV ketamine infusions eliminate any guesswork. Every molecule of medication is delivered directly into your bloodstream, ensuring consistency and predictability with each treatment. Think of it as having a direct line from the medication to the areas of your brain that need it most. This precision allows your doctor to tailor the dosage exactly to your needs, giving you maximum control over your treatment outcomes.
Spravato, on the other hand, relies on nasal absorption, which can vary from person to person. Factors like nasal congestion or how well the spray is administered can influence how much of the medication actually gets absorbed. Even though Spravato works for many people, this variability can sometimes make the results feel inconsistent.
IV ketamine delivers a full-strength dose directly to your brain—unlike Spravato, which loses more than half through nasal absorption and wears off faster.
How Molecular Differences Between IV (Racemic Ketamine) and Spravato (Esketamine) Affect Treatment Outcomes
IV ketamine contains both R- and S-ketamine, offering broader and longer-lasting antidepressant effects—while Spravato includes only S-ketamine, limiting its therapeutic range and potentially requiring more frequent treatment to maintain results.
Think of IV ketamine as a symphony, where every instrument contributes to a rich and complex performance, while Spravato is more like a solo act—impressive, but missing the depth of the full orchestra. The reason lies in the molecular composition of these treatments.
The ketamine in IV is made up of two mirror-image molecules, known as R-ketamine and S-ketamine. These enantiomers interact differently with receptors in the brain, producing distinct effects:
R-ketamine
Emerging research suggests this molecule may have longer-lasting and more potent antidepressant effects. It appears to exert its impact through mechanisms beyond just NMDA receptor antagonism, including promoting neuroplasticity—the brain’s ability to form and reorganize connections. R-ketamine also has a weaker dissociative effect compared to S-ketamine, potentially reducing some of the side effects associated with treatment.
S-ketamine
Known for its quick-acting properties, S-ketamine works primarily through NMDA receptor antagonism, increasing glutamate activity. While it can rapidly reduce symptoms of depression, particularly suicidal ideation, its effects may not last as long as those of R-ketamine.
Why IV Ketamine is a Symphony
IV ketamine contains both R- and S-ketamine, combining the rapid relief of S-ketamine with the sustained benefits of R-ketamine. This dual-action approach not only provides faster symptom relief but also promotes longer-term mood stabilization and brain repair. The inclusion of R-ketamine is like adding harmonies to the melody—it brings depth and balance, creating a more comprehensive treatment effect.
For example, studies have shown that R-ketamine’s ability to enhance neuroplasticity may lead to more durable antidepressant effects, potentially reducing the frequency of maintenance treatments. This could be a key factor in why patients treated with IV ketamine often report greater overall improvement compared to those using Spravato.
Spravato: A Solo Performance
Spravato, on the other hand, contains only S-ketamine, leaving out the potentially critical contributions of R-ketamine. While S-ketamine’s quick action can be life-changing for those in acute crises, such as experiencing suicidal thoughts, it doesn’t address the broader spectrum of ketamine’s potential benefits.
This limitation is like hearing only the melody without the harmonies—it can still be beautiful and impactful, but it lacks the richness and complexity that make the experience truly transformative. By excluding R-ketamine, Spravato may require more frequent dosing or additional therapies to achieve the same long-term benefits as IV ketamine.
The Full Orchestra vs. the Soloist
Both R- and S-ketamine have unique and valuable properties, and IV ketamine leverages the strengths of both molecules to deliver a balanced, robust treatment. In contrast, Spravato’s singular focus on S-ketamine limits its range, potentially leaving out key benefits.
Key Takeaway: How Molecular Differences Impact Outcomes
IV ketamine combines the rapid action of S-ketamine with the sustained benefits of R-ketamine—while Spravato leaves out R-ketamine entirely, which may reduce its long-term effectiveness and flexibility.
How IV Ketamine’s Weight-Based Dosing vs Spravato’s Standard Doses May Affect Outcomes
This section explores how IV ketamine allows for real-time dose adjustment based on weight and response—while Spravato offers only two fixed-dose options, regardless of body size or treatment effect.
Think of depression as a lock and ketamine as the key—if the key doesn’t fit perfectly, it won’t unlock the relief you need. IV ketamine therapy excels in this regard by delivering weight-based dosing, tailored specifically to each patient’s body size and needs.
Why Weight-Based Dosing Matters
Spravato offers only two fixed doses—56 mg or 84 mg—regardless of body weight or individual needs. This means someone like me, a 186 lb male, receives the same dosage as a 120 lb female. It’s a one-size-fits-all approach that doesn’t account for the significant differences in body size or how individuals metabolize the drug.
In contrast, IV ketamine uses weight-based dosing, ensuring the treatment is tailored specifically to you. The standard dosage for depression is 0.5 mg per kilogram of body weight. For example:
-
●
A person weighing 120 lbs (approximately 54.5 kg) would receive 27.25 mg.
-
●
A person weighing 186 lbs (approximately 84.5 kg) would receive 42.25 mg.
This personalized approach ensures each patient gets the dose their body needs, maximizing effectiveness and minimizing the risk of underdosing or overdosing. It’s the difference between getting a custom-tailored suit and picking one off the rack—it simply fits better.
A Note on Dosing Comparisons
It’s important to recognize that you can’t make a direct, apples-to-apples comparison between IV ketamine and Spravato doses. Here’s why:
-
●
Administration method matters. With IV ketamine, 100% of the dose goes directly into your bloodstream, while with Spravato’s nasal spray, only 25-50% of the dose is absorbed. The rest is lost in the nasal passages or during metabolism.
-
●
Different compounds. Spravato contains only the S-ketamine molecule, while IV ketamine includes both R- and S-ketamine, which may affect how the drug works and how much is needed to achieve the desired effect.
This means that while the esketamine nasal spray Spravato’s doses seem higher on paper, the actual amount of ketamine reaching your system may be significantly lower than an equivalent IV ketamine dose. It’s another reason why IV ketamine often provides more predictable and consistent results.
Ketamine infusion’s individualized approach ensures the treatment fits the patient, like adjusting the tension on a stringed instrument to produce the perfect note. By contrast, Spravato’s one-size-fits-all approach can leave some patients underdosed or overdosed.
Adjustable if Patient Gains or Loses Weight
Depression treatment isn’t static—neither is your body. Weight fluctuations are common due to changes in appetite, activity levels, or even the depression itself. Unlike Spravato, IV ketamine doses can take into account changes in body weight. For example:
-
●
A patient weighing 180 lbs (81.5 kg) would receive a starting dose of 40.75 mg.
-
●
If the patient’s weight decreases to 170 lbs (77.1 kg), their dose can be adjusted to 38.55 mg.
This ensures the treatment remains as effective as possible while minimizing the risk of side effects from over- or underdosing. Fixed-dose treatments like Spravato simply don’t have this kind of flexibility—they offer the same dose regardless of weight changes, which can impact efficacy.
Fine-Tuned Based on Individual Response
No two people experience depression or respond to ketamine therapy in exactly the same way. With IV ketamine, providers can fine-tune the dose throughout the course of treatment, adjusting for how each patient responds.
For instance:
-
●
If a patient reports feeling dissociated for too long after a session, the provider might slightly decrease the dose to reduce this side effect.
-
●
Conversely, if the antidepressant effect isn’t as strong as expected, the dose might be increased by small increments to enhance results.
This ability to adjust in real-time helps optimize the therapeutic effect and ensures the treatment evolves with the patient’s needs.
Precise Adjustments by Tiny Amounts
IV ketamine offers unparalleled precision, allowing providers to make dose adjustments as small as 0.1 mg/kg. This level of control is crucial for finding the “sweet spot” where the medication is most effective without causing unnecessary side effects.
Imagine a patient starting at the standard 0.5 mg/kg dose:
-
●
If the response is too mild, the dose might be increased to 0.6 mg/kg, offering a more robust effect.
-
●
If the dose feels too intense, it might be decreased to 0.4 mg/kg, reducing side effects like dissociation or nausea.
This incremental approach is like tuning a radio dial to find the clearest signal—it allows providers to fine-tune the treatment until it’s just right for the individual.
Why This Matters
With ketamine IV infusion, every detail of the treatment is designed to fit the patient, not the other way around. This precision ensures the medication works as effectively as possible, reducing trial-and-error frustration and providing a smoother path to remission.
In comparison, the esketamine nasal spray’s fixed doses (56 mg or 84 mg) lack this adaptability. Patients must either accept the dose as-is or stop treatment altogether if it isn’t working for them.
IV ketamine offers precise, real-time dose adjustments based on weight and response—while Spravato comes in just two fixed doses, limiting flexibility and increasing the risk of underdosing or overdosing.
Which Ketamine Treatment Disrupts Your Life Less?
This section looks at how IV ketamine and Spravato differ in clinic time, number of appointments, travel demands, and overall disruption to work, childcare, and daily routines.
Spravato requires more sessions. That’s just a fact. Over the first six months, it’s 21 appointments. IV ketamine typically takes 11 to 18. That difference might not seem huge on paper—but it hits hard when you’re trying to plan your life around it.
IV Ketamine Infusions Save Significant Clinic Time vs Spravato Nasal Spray
With IV ketamine sessions averaging about 1 hour and 43 minutes compared to Spravato’s ~2 hours and 15 minutes, you’re spending roughly half an hour less at the clinic per visit. Half an hour doesn’t sound like much until you multiply it by every appointment, every ride, every workday you have to carve up to make this happen. Over a full course, that’s many extra hours of your life sitting in a medical chair instead of living it.
With IV ketamine sessions averaging 1 hour and 43 minutes compared to Spravato’s 2 hours and 15 minutes, you’ll spend about 32 minutes less at the clinic per visit. While half an hour might not seem dramatic, let’s look at what this means over the course of your full treatment.
Ride Logistics After Every Session Are a Hidden Burden
Time spent at the clinic is only half the burden. After every single session—IV or Spravato—you can’t drive home. That part is brutal in a way people don’t understand until they’re in it.
It’s not just “finding a ride.” It’s the ongoing mental labor of it:
-
●
texting and calling people to see who’s free
-
●
coordinating drop-off and pickup times
-
●
asking again even when you already feel like a burden
-
●
scrambling when someone cancels last minute
-
●
making two or three backup calls because plan A fell through
-
●
and when nobody can do it, paying $50–$60 for an Uber or Lyft you didn’t budget for
When you’re depressed, that kind of coordination can feel like trying to solve a puzzle with wet hands. The ride logistics become a second stressor layered on top of the illness you’re trying to treat. Because Spravato requires more visits, it multiplies that burden: more sessions means more ride scheduling, more chances for plans to fall apart, more money bled into transportation, and more “I’m sorry, can you take me again?”
Work Absences, Privacy Stress, and Childcare Disruption Add Up
Yes, clinics can usually schedule you late afternoon—often around 3 PM—so you might only miss half a day instead of a full one. That helps. But it doesn’t erase the problem.
-
●
Explaining repeated absences to a boss or HR. You don’t have to give details, but you do have to say you have a medical condition requiring frequent supervised treatment. For many people, that’s embarrassing, anxiety-producing, and feels like a quiet invasion of privacy.
-
●
Childcare and caregiving coverage. If you have kids or you’re responsible for someone else, every appointment triggers a domino line: who’s watching them, for how long, what if the clinic runs late, what if your ride is delayed.
-
●
Life disruption that stacks. One or two sessions is a disruption. Twenty-one sessions is a new routine built around illness. Even when the treatment works, the scheduling toll can make you feel like your life is being managed by a calendar instead of you.
Appointment Fatigue and Dropout Risk Are Higher With Spravato
Twenty-one appointments in six months means showing up again and again, even on days where you’re drained, foggy, or barely functional. That grind matters. The more often you have to do something hard, the more chances there are to miss, postpone, or drop out—not because you don’t care, but because the treatment itself starts to feel like another load you can’t carry. This is one reason Spravato tends to have higher dropout rates: the therapy becomes the burden.
Bottom Line: Both Treatments Disrupt Life, but Spravato Multiplies the Burden
Both IV ketamine and Spravato demand real sacrifices—rides, time off work, childcare juggling, and constant disruption. IV ketamine usually asks for fewer total visits and less time per visit, which can ease the schedule pressure a bit. Spravato adds more appointments and longer clinic stays, which means more opportunities for the logistics to grind you down. So this isn’t “IV is easy.” It’s that Spravato intensifies the same burdens by sheer repetition. And when you’re already fighting depression, repetition isn’t neutral—it’s weight.
What Are The Differences in Cost Between IV and Spravato and Does Insurance Cover Them?
| Treatment Option | Cost Per Treatment (Median) | # of Treatments | Total Cost (Median) | Notes |
|---|---|---|---|---|
| Spravato (No Insurance) | $1,050/session | 21 | $22,050 | Self-pay pricing varies by clinic. 21 sessions is the standard FDA protocol for the first 6 months. |
| Spravato (With Insurance Only) | $286/session | 21 | $6,000 | Based on typical insurance: $2,000 deductible, $6,000 out-of-pocket max, 20% coinsurance. Costs can shift dramatically based on your plan. 21 sessions is the standard FDA protocol for the first 6 months. |
| Spravato (Insurance + Manufacturer Subsidy) | $135/session | 21 | $2,835 | Assumes typical insurance plus manufacturer copay support for eligible patients. 21 sessions is the standard FDA protocol for the first 6 months. |
| IV Ketamine | $590/infusion | 15 | $7,975 | Number of infusions ranges from 11 to 18 depending on each individual—we chose 15 as a typical acute + early maintenance course based on common clinic protocols. |
* IV: Costs vary widely by city size. That’s why we use the median—the middle value where half of prices are higher and half lower. It’s a realistic planning number: expect lower costs in smaller cities like Des Moines and higher in major metros like New York City.
** Spravato: insurance costs vary widely depending on your plan details—your deductible and how much of it you’ve already paid, your out-of-pocket maximum and how close you are to hitting it, and your coinsurance rate (for example, whether you pay 20% or 30% of each visit).
IV Ketamine vs Spravato Costs: What This Table Means in Plain English
This table compares typical six-month costs. It assumes about 21 Spravato sessions in six months, and a typical IV ketamine course of about 15 infusions. The big idea is simple: Spravato usually costs less when insurance covers it, and IV usually costs less when Spravato is not covered.
Cost Scenario 1: Spravato Without Insurance Is Much More Expensive Than IV
The table shows Spravato without insurance at about $22,050 for six months. IV ketamine is about $7,975 for a typical course. So if Spravato is cash-pay for you, IV is clearly the cheaper option by a very large margin. (You may qualify for no-insurance help from the manufacturer but it will still be a lot more expensive than IV).
Cost Scenario 2: Spravato With Insurance (No Subsidy) Is Usually Cheaper Than IV
Spravato with insurance costs around $6,000 for six months, compared to IV at about $7,975. That means, in most normal insurance situations, the nasal spray has a cost advantage.
The main exception is when your Spravato copay per visit is high. A simple rule: if your out-of-pocket Spravato cost is more than about $380 per session, IV becomes cheaper overall. That is because Spravato requires more sessions, so costs add up faster.
Here’s the plain-language math behind that rule. A typical IV course in your table totals about $7,975. Spravato requires 21 visits in six months. If your Spravato copay is $380 per visit, then $380 × 21 = $7,980 — basically the same as the typical IV total. That’s why $380 is the break-even point. If your Spravato copay is higher than that — say $400 — then $400 × 21 = $8,400, which is clearly more than $7,975. So even though one IV visit can cost more, Spravato can cost more overall because you have to pay for more sessions.
And remember: IV prices swing a lot by city. In smaller or lower-cost areas, IV infusions can run closer to $400 each, which pulls the IV total down fast. Spravato’s drug price is basically national, and what you pay mostly depends on your insurance, though clinic fees and plan rules can still cause some variation. Net: Spravato with insurance usually has the cost edge — unless your copay is high or your local IV price is low.
Cost Scenario 3: Spravato With Insurance Plus Manufacturer Subsidy Is the Cheapest Option
If you qualify for the manufacturer copay support, the table shows Spravato dropping to about $2,835 for six months. In that case, Spravato is far cheaper than IV.
If Cost Is the Only Thing You Care About, Here’s the Simple Takeaway
-
1
No insurance for Spravato: IV costs much less.
-
2
Insurance covers Spravato: Spravato usually costs less.
-
3
Insurance plus subsidy: Spravato is the lowest-cost option by a wide margin.
Then Add Effectiveness: How Much More Is Worth Paying?
After you know which one is cheaper in your situation, the next question is how much extra cost, if any, is worth paying for a treatment that may work better or faster for some people. If IV ends up only a little more expensive than Spravato for you, some people decide that the possible effectiveness edge is worth that difference. If IV is much more expensive for you, others start with Spravato because it is the affordable option they can realistically complete.
In short: Spravato tends to win on price when it is covered, IV tends to win on price when Spravato is not. Once you see your price difference, you can decide whether paying more for IV’s potential benefit makes sense for you.
How Long IV Ketamine and Spravato Have Been Studied for Depression
Studies Began in the Late 1990s, Giving IV Ketamine a Two-Decade Edge Over Spravato, Approved in 2019
This section looks at why IV ketamine has a longer research history than Spravato, what kinds of trials have been done, and how that affects clinical confidence in each treatment.
Research on IV ketamine began over two decades ago, starting in the late 1990s with groundbreaking studies at Yale. By 2000, key findings established IV ketamine as a potential game-changer for treatment-resistant depression. In contrast, Spravato (esketamine nasal spray) was only approved by the FDA in March 2019, giving IV ketamine a 20-year research head start.
Why Does a 20-Year Advantage Matter?
A longer research history means more studies, more data, and more insights into how a treatment works—and for whom. With two decades of research, IV ketamine has benefited from:
-
●
A Larger Body of Evidence: Since the early 2000s, hundreds of studies have explored IV ketamine for depression, covering a wide range of topics, including dosing strategies, mechanisms of action, long-term outcomes, and its use for comorbid conditions like anxiety and PTSD. This cumulative research provides a robust foundation for understanding IV ketamine’s potential.
-
●
Diverse Study Designs: IV ketamine has been studied in both controlled clinical trials and real-world settings, offering insights not just into how it works in labs but also in the day-to-day lives of patients. Studies have also explored long-term follow-ups, giving a clearer picture of its sustained effects over months or even years.
-
●
Informed Clinical Practice: The wealth of data on IV ketamine has helped refine its use in clinical settings. Today, treatment protocols are based on decades of research and real-world experience, providing clinicians with greater confidence in tailoring treatments to individual patients.
Spravato: Newer and Less Established
Spravato, while rigorously tested for FDA approval, simply hasn’t been studied as extensively. Its development began more recently, and the data available primarily focus on short-term outcomes from clinical trials rather than long-term or real-world effectiveness.
For example:
-
●
IV ketamine has been evaluated in a wider range of patient populations, including those with treatment-resistant depression, bipolar depression, and PTSD.
-
●
Spravato’s research is primarily limited to FDA-required studies for treatment-resistant depression and major depressive disorder with acute suicidal ideation. See my rant on why the FDA should approve IV ketamine.
The Benefits of a 20-Year Research Lead
The extensive research on IV ketamine offers clear benefits for patients:
-
●
Confidence in Safety and Efficacy: Decades of studies provide a deeper understanding of potential side effects and how to minimize them. This ensures a high level of safety and predictability during treatment.
-
●
Tailored Treatment Protocols: The wealth of data allows clinicians to customize dosing and schedules for individual patients, leading to more effective and personalized care.
-
●
Real-World Insights: Long-term and real-world studies give patients and providers confidence in the sustained benefits of IV ketamine, which are still being established for Spravato.
IV ketamine’s 20-year head start in research isn’t just an academic advantage—it translates directly into better-informed treatment options for patients. With a larger body of evidence, refined protocols, and real-world data, IV ketamine stands on a foundation of trust and proven results that Spravato has yet to match.
IV ketamine has 20+ years of real-world research in depression—while Spravato’s shorter trial history leaves bigger gaps about long-term use and everyday effectiveness.
FAQs About IV Ketamine vs Spravato
Which is more effective for the treatment of depression—IV ketamine or the esketamine nasal spray Spravato?
Early on, IV ketamine is the heavier hitter: up to 30% remission within 1–2 infusions, reliable bioavailability, tailored dosing, fewer visits, shorter stays. It’s reasonable to expect those advantages to carry forward and possibly outperform Spravato over months.
Still, that’s guidance, not statistics. The evidence bases are mismatched—IV studies focus on the first few sessions; Spravato studies track 8–21+. Until we see head-to-head trials with the same schedules and long-term remission reporting, the long-run verdict remains open.
What do remission rates show when both treatments are combined with therapy?
Remission rates for IV ketamine and Spravato are typically modeled from placebo-controlled studies where therapy wasn’t part of the trial. To reflect real-world use, we’ve added conservative estimates of psychotherapy’s contribution to remission.
Research shows that adding therapy to SSRIs can boost response rates by 25%—a pattern that likely holds true for ketamine as well. That means psychotherapy isn’t just an add-on; it’s a force multiplier, increasing the chance of remission no matter which treatment method you choose.
That means combining IV ketamine or Spravato with therapy gives you a significantly better shot at full recovery than using either one alone.
How fast can I expect results from IV ketamine, and how does that timeline compare to Spravato?
IV ketamine usually works faster. About 1 in 3 patients reach remission after just one or two infusions (at least initially). Most feel noticeable relief within the first week.
Spravato can still work quickly—it’s considered fast-acting compared to traditional antidepressants—but meaningful results often take several weeks and multiple doses. For patients in crisis, that delay can make a difference. And if either treatment doesn’t help by the 6–8 session mark, your doctor may recommend changing course.
That means IV ketamine may bring life-changing results in days—not weeks—while Spravato often requires more time and patience to take full effect.
How many sessions will I need with IV ketamine or Spravato, and what does that mean for my schedule?
Most people need between 11 and 18 IV ketamine infusions over the first 6 months. Spravato requires 21 sessions in that same period. IV treatments usually taper off after the first month, while Spravato stays on a fixed schedule much longer.
Each IV session takes about 90 minutes. Each Spravato visit lasts 2+ hours and includes mandatory monitoring. That means more time off work, more rides to the clinic, and more logistical juggling with Spravato.
That means IV ketamine takes fewer total appointments and less time per visit—making it easier to sustain if your life is already stretched thin.
How much of the medication actually reaches the brain with IV ketamine vs Spravato?
IV ketamine delivers 100% of the medication directly into your bloodstream. Every milligram gets absorbed.
Spravato has a nasal bioavailability of about 48%, meaning over half of each dose is lost during absorption. And that number isn’t stable—it can drop even lower if you’re congested, have allergies, or don’t spray correctly.
With IV, absorption is consistent and reliable. With Spravato, there’s always some guesswork.
That means IV ketamine gives you the full dose every time—while Spravato varies based on how well your body absorbs the nasal spray.
Can my ketamine dose be adjusted based on my body and response, and why is that important?
Yes—with IV ketamine, the dose can be customized for your weight, symptoms, and how you respond over time. Providers can start low and increase slowly, adjusting by as little as 0.1 mg/kg.
If your weight changes or side effects appear, the dose can shift accordingly. Spravato doesn’t allow that. You get 56 mg or 84 mg—same for a 120 lb woman or a 200 lb man. No titration. No personalization.
That means IV ketamine gives you a flexible dose that fits your body—while Spravato sticks to a one-size-fits-all approach.
What Does Scientific Research Show About IV Ketamine’s Effectiveness For Depression?
I pulled together 33 systematic reviews from the last five years into one report—so you don’t have to rely on hype, guesses, or anecdotes. This is the highest level of real-world evidence we have.
Inside My Report You’ll Find
- What percent of patients enter remission—broken down by delivery method
- Which method is most effective—IV, injection, or Spravato nasal spray
- How fast ketamine can work to reduce or end symptoms
- Which combinations (like psychotherapy) may enhance response
- And a lot more…
Verified by the Platforms That Matter
This research summary report has been published across four trusted platforms that host peer-reviewed or open science content, including:
– Published ketamine research on Zenodo
– Ketamine evidence summary hosted on SSRN
– Scientific report on ketamine outcomes on Figshare
– Evidence-based ketamine therapy report on OSF